Medcaptain Medical Technology Co Ltd (Ticker: 2041 HK) is a Chinese medical device company providing products across life support, minimally invasive intervention and in vitro diagnostics. Its portfolio includes infusion systems, endoscopic products, diagnostic analyzers and related consumables, with products distributed in more than 140 countries and regions and used in over 6,000 hospitals in China.

Medcaptain plans to list on the Hong Kong Stock Exchange on September 7, 2026. The company is offering approximately 38.91 million H shares at HKD 15.42 per share, raising approximately HKD 600 million (approximately $77 million). The offering consists entirely of primary shares. Based on the offer terms, Medcaptain is valued at approximately $943 million at the IPO price.

The company operates five R&D centers and six manufacturing centers across China and the UK. Revenue increased from RMB1.31 billion in 2023 to RMB1.62 billion in 2025, while gross margin rose to 53.7% in 2025. Medcaptain reported net profit of RMB50.7 million in 2025.